Search
Alkermes Plc
ALKSAdd to Watchlist
45.900USD
+1.360+3.05%
Close 11-06 16:00（ET）
7.70BMarket Cap
49.40P/E TTM
After-hours 18:30 (ET)46.010USD+0.160+0.35%
After-hours 18:30 (ET)Today
+3.05%
5 Days
+1.24%
1 Month
+10.20%
6 Months
+29.95%
Year to Date
+64.05%
1 Year
+44.89%
Key Figures
44.190Open
44.650High
281.23KVolume
49.40P/E TTM
72.83P/E Dynamic
--Dividend TTM
0.17%Turnover Ratio
44.540Prev. Close
44.070Low
12.77MTurnover
20.99P/E Static
4.13P/B
0.00%Div Yield TTM
4.82%ROA
55.67052wk High
59.54Volume Ratio
367.07MNet Profit
167.76MShares
0.9298EPS TTM
0.31Beta
9.36%ROE
27.00052wk Low
5.56%Amplitude
77.51%Gross Margin
7.70BMarket Cap
-2.28Reward/Risk
2.55%Risk Rate
Alkermes Plc's Score
0.03vs previous score
Forecast7.70
Financial Health8.22
Technical4.29
Valuation Dimensions8.77
Institutional Confidence10.00
Risk Assessment7.49
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Alkermes Plc Technical Analysis
Technical Indicators
Sell
Summary
Neutral
Moving Average
Strong buy
Alkermes Plc Latest Earnings Call Transcripts
Alkermes (ALKS) Q3 2026 Earnings Call: $480.1M Revenue and Orexin Catalysts
Alkermes Q3 2026 revenue reached $480.1 million as proprietary sales rose 31%. Management maintained guidance and outlined six upcoming orexin readouts.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
0.10/-0.07
Revenue / Forecast
480.13M/463.61M
Alkermes Plc Profile
SectorBiotechnology & Medical Research
Ticker SymbolALKS
Number of employees1800
CountryIreland
Ownership
| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 14.44% |
| Baker Bros. Advisors LP | 6.01% |
| Vanguard Portfolio Management, LLC | 5.71% |
| State Street Investment Management (US) | 5.68% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 53.46% |
| Investment Advisor/Hedge Fund | 29.75% |
| Hedge Fund | 19.22% |
| Research Firm | 2.48% |
Related Instruments
-0.79%
+1.43%
+1.07%
-0.14%
+0.38%
-0.22%
+0.03%
-0.41%
+0.02%
-0.20%
+0.85%
-1.57%
-1.04%
+0.28%
+5.27%
-0.16%
+0.16%
-0.80%
+1.46%
+3.63%Popular Instruments
51290.600
-208.500 (-0.41%)
26964.500
+329.300 (+1.24%)
7380.000
+23.100 (+0.31%)
12797.000
-1.000 (-0.01%)
58142.000
+876.000 (+1.53%)
6140.600
-37.200 (-0.60%)
89.857
-0.176 (-0.20%)
342.370
-1.800 (-0.52%)
186.640
+5.040 (+2.78%)
4065.670
-33.020 (-0.81%)
FAQs
What is the current price of Alkermes Plc (ALKS)?
The current price of Alkermes Plc (ALKS) is 45.90.
What is the symbol of Alkermes Plc?
The ticker symbol of Alkermes Plc is ALKS.
What is the 52-week high of Alkermes Plc?
The 52-week high of Alkermes Plc is 55.67.
What is the 52-week low of Alkermes Plc?
The 52-week low of Alkermes Plc is 27.00.
What is the market capitalization of Alkermes Plc?
The market capitalization of Alkermes Plc is 7.70B.
Is Alkermes Plc (ALKS) currently rated as Buy, Hold, or Sell?
According to analysts, Alkermes Plc (ALKS) has an overall rating of Buy, with a price target of 56.26.
What is the Earnings Per Share (EPS TTM) of Alkermes Plc (ALKS)?
The Earnings Per Share (EPS TTM) of Alkermes Plc (ALKS) is 0.93.